ASTRAZENECA PLC-SPONS ADR (AZN) Fundamental Analysis & Valuation

NYSE:AZN • US0463531089

Current stock price

189.75 USD
-2.55 (-1.33%)
At close:
189.5 USD
-0.25 (-0.13%)
After Hours:

This AZN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

9

1. AZN Profitability Analysis

1.1 Basic Checks

  • In the past year AZN was profitable.
  • In the past year AZN had a positive cash flow from operations.
  • AZN had positive earnings in each of the past 5 years.
  • AZN had a positive operating cash flow in each of the past 5 years.
AZN Yearly Net Income VS EBIT VS OCF VS FCFAZN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

1.2 Ratios

  • AZN has a better Return On Assets (8.96%) than 90.05% of its industry peers.
  • AZN has a better Return On Equity (21.01%) than 91.62% of its industry peers.
  • AZN has a better Return On Invested Capital (13.63%) than 92.67% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 13.11%.
  • The last Return On Invested Capital (13.63%) for AZN is above the 3 year average (12.48%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROIC 13.63%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
AZN Yearly ROA, ROE, ROICAZN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 17.41%, AZN belongs to the top of the industry, outperforming 90.05% of the companies in the same industry.
  • In the last couple of years the Profit Margin of AZN has grown nicely.
  • Looking at the Operating Margin, with a value of 23.86%, AZN belongs to the top of the industry, outperforming 91.10% of the companies in the same industry.
  • In the last couple of years the Operating Margin of AZN has grown nicely.
  • The Gross Margin of AZN (81.31%) is better than 86.39% of its industry peers.
  • AZN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
AZN Yearly Profit, Operating, Gross MarginsAZN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

4

2. AZN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AZN is still creating some value.
  • The number of shares outstanding for AZN remains at a similar level compared to 1 year ago.
  • The number of shares outstanding for AZN has been increased compared to 5 years ago.
  • Compared to 1 year ago, AZN has an improved debt to assets ratio.
AZN Yearly Shares OutstandingAZN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
AZN Yearly Total Debt VS Total AssetsAZN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B 100B

2.2 Solvency

  • An Altman-Z score of 3.80 indicates that AZN is not in any danger for bankruptcy at the moment.
  • AZN has a Altman-Z score of 3.80. This is in the better half of the industry: AZN outperforms 68.59% of its industry peers.
  • AZN has a debt to FCF ratio of 3.42. This is a good value and a sign of high solvency as AZN would need 3.42 years to pay back of all of its debts.
  • AZN has a better Debt to FCF ratio (3.42) than 89.53% of its industry peers.
  • AZN has a Debt/Equity ratio of 0.55. This is a neutral value indicating AZN is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.55, AZN is doing worse than 67.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Altman-Z 3.8
ROIC/WACC1.55
WACC8.8%
AZN Yearly LT Debt VS Equity VS FCFAZN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.3 Liquidity

  • A Current Ratio of 0.94 indicates that AZN may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.94, AZN is doing worse than 88.48% of the companies in the same industry.
  • A Quick Ratio of 0.72 indicates that AZN may have some problems paying its short term obligations.
  • AZN has a Quick ratio of 0.72. This is amonst the worse of the industry: AZN underperforms 86.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.94
Quick Ratio 0.72
AZN Yearly Current Assets VS Current LiabilitesAZN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

5

3. AZN Growth Analysis

3.1 Past

  • AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 11.57%, which is quite good.
  • The Earnings Per Share has been growing by 17.91% on average over the past years. This is quite good.
  • The Revenue has grown by 8.63% in the past year. This is quite good.
  • Measured over the past years, AZN shows a quite strong growth in Revenue. The Revenue has been growing by 17.15% on average per year.
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.35% on average over the next years. This is quite good.
  • Based on estimates for the next years, AZN will show a small growth in Revenue. The Revenue will grow by 6.31% on average per year.
EPS Next Y14.55%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
EPS Next 5Y11.35%
Revenue Next Year7.34%
Revenue Next 2Y6.88%
Revenue Next 3Y6.56%
Revenue Next 5Y6.31%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AZN Yearly Revenue VS EstimatesAZN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
AZN Yearly EPS VS EstimatesAZN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

6

4. AZN Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 20.56 indicates a rather expensive valuation of AZN.
  • Based on the Price/Earnings ratio, AZN is valued cheaper than 82.20% of the companies in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 27.42, AZN is valued a bit cheaper.
  • With a Price/Forward Earnings ratio of 17.94, AZN is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of AZN indicates a somewhat cheap valuation: AZN is cheaper than 79.58% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.24, AZN is valued at the same level.
Industry RankSector Rank
PE 20.56
Fwd PE 17.94
AZN Price Earnings VS Forward Price EarningsAZN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 81.15% of the companies in the same industry are more expensive than AZN, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AZN indicates a rather cheap valuation: AZN is cheaper than 80.63% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 33.94
EV/EBITDA 16.27
AZN Per share dataAZN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • AZN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • AZN has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as AZN's earnings are expected to grow with 12.24% in the coming years.
PEG (NY)1.41
PEG (5Y)1.15
EPS Next 2Y13.63%
EPS Next 3Y12.24%

7

5. AZN Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 1.59%, AZN has a reasonable but not impressive dividend return.
  • AZN's Dividend Yield is rather good when compared to the industry average which is at 0.68. AZN pays more dividend than 91.10% of the companies in the same industry.
  • AZN's Dividend Yield is comparable with the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 1.59%

5.2 History

  • The dividend of AZN has a limited annual growth rate of 3.33%.
  • AZN has paid a dividend for at least 10 years, which is a reliable track record.
  • AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)3.33%
Div Incr Years2
Div Non Decr Years12
AZN Yearly Dividends per shareAZN Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1 2 3

5.3 Sustainability

  • 48.62% of the earnings are spent on dividend by AZN. This is a bit on the high side, but may be sustainable.
  • The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP48.62%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
AZN Yearly Income VS Free CF VS DividendAZN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B 10B
AZN Dividend Payout.AZN Dividend Payout, showing the Payout Ratio.AZN Dividend Payout.PayoutRetained Earnings

AZN Fundamentals: All Metrics, Ratios and Statistics

ASTRAZENECA PLC-SPONS ADR

NYSE:AZN (4/24/2026, 8:22:25 PM)

After market: 189.5 -0.25 (-0.13%)

189.75

-2.55 (-1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-10
Earnings (Next)04-29
Inst Owners52.17%
Inst Owner Change-99.02%
Ins Owners0.04%
Ins Owner Change0%
Market Cap294.27B
Revenue(TTM)58.74B
Net Income(TTM)10.22B
Analysts81.67
Price Target222.94 (17.49%)
Short Float %0.11%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield 1.59%
Yearly Dividend3.21
Dividend Growth(5Y)3.33%
DP48.62%
Div Incr Years2
Div Non Decr Years12
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.02%
Min EPS beat(2)-1.5%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)1.89%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)1.32%
EPS beat(12)7
Avg EPS beat(12)2.08%
EPS beat(16)11
Avg EPS beat(16)3.17%
Revenue beat(2)0
Avg Revenue beat(2)-1.57%
Min Revenue beat(2)-2.88%
Max Revenue beat(2)-0.26%
Revenue beat(4)0
Avg Revenue beat(4)-1.84%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)-0.24%
Revenue beat(8)3
Avg Revenue beat(8)0%
Revenue beat(12)4
Avg Revenue beat(12)-0.5%
Revenue beat(16)5
Avg Revenue beat(16)-0.51%
PT rev (1m)7.17%
PT rev (3m)127.97%
EPS NQ rev (1m)-1.37%
EPS NQ rev (3m)92.68%
EPS NY rev (1m)-0.83%
EPS NY rev (3m)101.98%
Revenue NQ rev (1m)0.89%
Revenue NQ rev (3m)1.13%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)1.45%
Valuation
Industry RankSector Rank
PE 20.56
Fwd PE 17.94
P/S 5.01
P/FCF 33.94
P/OCF 20.19
P/B 6.05
P/tB N/A
EV/EBITDA 16.27
EPS(TTM)9.23
EY4.86%
EPS(NY)10.57
Fwd EY5.57%
FCF(TTM)5.59
FCFY2.95%
OCF(TTM)9.4
OCFY4.95%
SpS37.88
BVpS31.38
TBVpS-6.72
PEG (NY)1.41
PEG (5Y)1.15
Graham Number80.7285 (-57.46%)
Profitability
Industry RankSector Rank
ROA 8.96%
ROE 21.01%
ROCE 16.8%
ROIC 13.63%
ROICexc 14.63%
ROICexgc 59.47%
OM 23.86%
PM (TTM) 17.41%
GM 81.31%
FCFM 14.76%
ROA(3y)7.2%
ROA(5y)5.03%
ROE(3y)17.82%
ROE(5y)12.53%
ROIC(3y)12.48%
ROIC(5y)10.5%
ROICexc(3y)13.49%
ROICexc(5y)11.39%
ROICexgc(3y)81.92%
ROICexgc(5y)83.55%
ROCE(3y)15.36%
ROCE(5y)12.92%
ROICexgc growth 3Y-25.55%
ROICexgc growth 5Y0.81%
ROICexc growth 3Y9.13%
ROICexc growth 5Y9.72%
OM growth 3Y6.24%
OM growth 5Y7.63%
PM growth 3Y32.91%
PM growth 5Y7.71%
GM growth 3Y0.34%
GM growth 5Y0.28%
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.55
Debt/FCF 3.42
Debt/EBITDA 1.36
Cap/Depr 103%
Cap/Sales 10.05%
Interest Coverage 10.65
Cash Conversion 73.79%
Profit Quality 84.79%
Current Ratio 0.94
Quick Ratio 0.72
Altman-Z 3.8
F-Score7
WACC8.8%
ROIC/WACC1.55
Cap/Depr(3y)80.57%
Cap/Depr(5y)64.46%
Cap/Sales(3y)8.93%
Cap/Sales(5y)7.69%
Profit Quality(3y)99.49%
Profit Quality(5y)775.68%
High Growth Momentum
Growth
EPS 1Y (TTM)11.57%
EPS 3Y11.21%
EPS 5Y17.91%
EPS Q2Q%1.44%
EPS Next Y14.55%
EPS Next 2Y13.63%
EPS Next 3Y12.24%
EPS Next 5Y11.35%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y9.82%
Revenue growth 5Y17.15%
Sales Q2Q%4.11%
Revenue Next Year7.34%
Revenue Next 2Y6.88%
Revenue Next 3Y6.56%
Revenue Next 5Y6.31%
EBIT growth 1Y10.05%
EBIT growth 3Y16.67%
EBIT growth 5Y26.09%
EBIT Next Year25.58%
EBIT Next 3Y14.44%
EBIT Next 5Y10.4%
FCF growth 1Y19.18%
FCF growth 3Y6.21%
FCF growth 5Y31.64%
OCF growth 1Y22.88%
OCF growth 3Y14.12%
OCF growth 5Y24.88%

ASTRAZENECA PLC-SPONS ADR / AZN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?

ChartMill assigns a fundamental rating of 6 / 10 to AZN.


What is the valuation status for AZN stock?

ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.


What is the profitability of AZN stock?

ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.


What is the valuation of ASTRAZENECA PLC-SPONS ADR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 20.56 and the Price/Book (PB) ratio is 6.05.


Is the dividend of ASTRAZENECA PLC-SPONS ADR sustainable?

The dividend rating of ASTRAZENECA PLC-SPONS ADR (AZN) is 7 / 10 and the dividend payout ratio is 48.62%.